Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Your program will be tailored to your health goals for this one low price
Allergic reactions to semaglutide may manifest as anaphylaxis, angioedema, or severe hypersensitivity reactions, though these are relatively rare
The state has a high prevalence of obesity, diabetes, and cardiovascular disease, particularly in rural and underserved areas
Moreover, the results from the PIONEER clinical trials suggested that oral semaglutide effectively reduced HbA1c and body weight, showing responsiveness in diverse age groups with a diagnosis of DM2 (54)
Co-administration leads to greater reductions in albuminuria and more pronounced initial declines in eGFR, indicative of reduced intraglomerular pressure [122,123]
